Certara (NASDAQ:CERT) Shares Down 4.6% – Time to Sell?

Certara, Inc. (NASDAQ:CERT) shares dropped 4.6% on Thursday . The company traded as low as $10.39 and last traded at $10.42. Approximately 216,356 shares changed hands during trading, a decline of 74% from the average daily volume of 838,846 shares. The stock had previously closed at $10.92.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Barclays decreased their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Finally, Robert W. Baird lowered their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $15.92.

Certara Trading Up 1.5 %

The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The stock has a market capitalization of $1.72 billion, a P/E ratio of -53.55, a price-to-earnings-growth ratio of 5.86 and a beta of 1.53. The stock has a 50-day moving average price of $10.81 and a two-hundred day moving average price of $12.46.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.06 EPS. On average, research analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Activity at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.39% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Certara

Several large investors have recently modified their holdings of the stock. Blue Trust Inc. bought a new position in shares of Certara during the second quarter valued at $26,000. Innealta Capital LLC purchased a new stake in Certara during the 2nd quarter valued at $36,000. KBC Group NV lifted its holdings in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after buying an additional 1,584 shares during the period. Intech Investment Management LLC purchased a new position in shares of Certara in the 2nd quarter worth $152,000. Finally, Algert Global LLC purchased a new position in shares of Certara in the 2nd quarter worth $156,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.